Independent Sector Cancer Network (ISCN) Publish NEW Cancer Service Guidelines

The Independent Sector Cancer Network (ISCN) is a strategic quality governance and safety group which aims to improve independard sector cancer provision though effective collaboration and sharing of best practice across the Independent Sector Cancer Services within the UK.

The ISCN is comprised of expert members who are senior leaders in cancer care, representing nursing, therapeutic radiology, and pharmacy. Over the past years, our team has diligently worked on developing these guidelines to be implemented across the independent sector, aiming to standardise and elevate clinical practice. Although led by the ISCN, this document has transferability to all cancer services.

The ISCN Cancer Service Guidelines 2024 are now readily available for use. These guidelines are designed to:

  • Guide quality of care in practice: Providing a comprehensive framework to ensure the highest standards of patient care.
  • Offer a benchmarking framework: Enabling teams to measure and compare their practices against established standards.
  • Standardize clinical practice: Ensuring consistency and excellence in cancer care across the independent sector.

The ISCN believes these guidelines will significantly contribute to improving patient outcomes and fostering a culture of continuous improvement in cancer care. The ISCN would encourage all teams to integrate these guidelines into their daily practice and use them as a tool for achieving excellence in patient care.

To access the guidelines please click here: https://www.bopa.org.uk/resources/iscn-cancer-service-guidelines/

Please note you need to be a free or paid member of BOPA to access.

Thank you for your commitment to advancing cancer care.

Best regards,
Independent Sector Cancer Network (ISCN)

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article